Revolution Medicines to Participate in March 2025 Investor Conferences
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in three major investor conferences in March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its participation in three major investor conferences in March 2025.
The company's CEO and chairman, Mark A. Goldsmith, M.D., Ph.D., will participate in fireside chats at:
- TD Cowen 45th Annual Healthcare Conference on March 3 at 1:50 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on March 11 at 8:00 a.m. ET
- 2025 Leerink Partners Global Healthcare Conference on March 12 at 2:20 p.m. ET
Live webcasts of these events will be available on the company's investor relations website, with replays accessible for at least 14 days following the presentations.
Details
News Market Reaction – RVMD
The recorded move for RVMD in the trading session of this news was +0.27%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in three upcoming investor conferences.
Details of the company’s participation are as follows:
- TD Cowen 45th Annual Healthcare Conference
- Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET
- Barclays 27th Annual Global Healthcare Conference
- Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET
- 2025 Leerink Partners Global Healthcare Conference
- Fireside Chat Date/Time: Wednesday, March 12 at 2:20 p.m. ET
To listen to a live webcast of any of these events, or access archived webcasts, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcasts, replays will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.